A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Sponsored by Alnylam Pharmaceuticals
About this trial
Last updated 4 days ago
Study ID
Status
Type
Phase
Placebo
Accepting
Trial Timing
Started a year ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
Part A: - Has a body mass index (BMI) of ≥27 kg/m^2 and <40 kg/m^2 Part B: - Is an adult patient with a confirmed diagnosis of T2DM - Has a hemoglobin A1c (HbA1c) ≥7% to <10.5% - Has a BMI of ≥25 kg/m^2 and <45 kg/m^2 - Is on a stable dose of either metformin or metformin and a sodium-glucose cotransporter 2 inhibitor (SGLT2i)
Exclusion Criteria
Part A: - Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection Part B: - Receiving therapies for chronic weight management or antidiabetic medications other than metformin and SGLT2i Note: other protocol defined inclusion/exclusion criteria apply
For more information, view the full study details:
NCT06845202